Nouveau spectre des troubles cognitifs liés à l'infection par le VIH à l'ère des trithérapies
|Published in||Revue médicale suisse. 2009, vol. 5, no. 201, p. 955-956, 958-961|
|Abstract||Highly active anti-retroviral therapy (HAART) has almost abolished HIV-related mortality and serious opportunistic diseases; among them, AIDS-related dementia. However, minor forms of cognitive dysfunction, have not disappeared, and even increased in frequency. Ageing of HIV+ patients, insufficient penetration of anti-viral drugs into the brain with continuous low-grade viral production and inflammation may play a role. Minor cognitive dysfunction in HIV infection shares some clinical and pathophysiological features with neuro-degenerative diseases, in particular Alzheimers disease. It can thus be postulated that, such in Alzheimer disease, anti-cholinesterase drugs might also be efficacious in AIDS-related minor cognitive dysfunction. This hypothesis has not been tested yet however A clinical trial using ravistigmine is starting this spring in patients with HIV-associated cognitive dysfunction in Geneva and Lausanne.|
|Keywords||Algorithms — Antiretroviral Therapy, Highly Active — Cognition Disorders/ etiology — HIV Infections/ complications/drug therapy — Humans|
This document has no fulltext available yet, but you can contact its author by using the form below.
|DU PASQUIER, R. et al. Nouveau spectre des troubles cognitifs liés à l'infection par le VIH à l'ère des trithérapies. In: Revue médicale suisse, 2009, vol. 5, n° 201, p. 955-956, 958-961. https://archive-ouverte.unige.ch/unige:9311|